Literature DB >> 24446969

IFN-γ release assay conversions and reversions. Challenges with serial testing in U.S. health care workers.

Manish Joshi1, Thomas P Monson, Anita Joshi, Gail L Woods.   

Abstract

RATIONALE: IFN-γ release assays (IGRAs) including the QuantiFERON-TB gold in-tube test (QFT-GIT) are increasingly used in place of the tuberculin skin test (TST) in surveillance programs for Mycobacterium tuberculosis infection in the United States. However, data on conversions, reversions, and predictive value of QFT in such programs for health care workers (HCWs) are limited.
OBJECTIVES: The purpose of this study is to assess long-term reproducibility and conversion and reversion rates of QFT-GIT among HCWs who underwent serial testing at a tertiary care center in the United States.
METHODS: Retrospective chart review of HCWs at the Central Arkansas Veterans Healthcare System (CAVHS) who underwent serial testing with QFT-GIT as a part of their employee screening between November 1, 2008 and January 31, 2011.
MEASUREMENTS AND MAIN RESULTS: A total of 2,303 HCWs had at least 2 QFT-GITs 1 year apart. The initial QFT-GIT was positive for 69 and 2 were indeterminate. Of these 69 HCWs, 31 (45%) reverted on repeat testing, and 25 of 31 (80.6%) HCWs who reverted had a negative look-back TST. Of the 2,232 HCWs with an initial negative QFT-GIT, 71 (3.2%) converted on repeat testing. A third QFT-GIT assay was performed in 41 of the 71 converters and 90% (37 of 41) reverted back to negative. Only two HCWs had TST and QFT-GIT conversion.
CONCLUSIONS: Poor IGRA reproducibility and a low predictive value of QFT-GIT conversions indicate that QFT-GIT with current interpretation criteria should not be used for serial screening of U.S. HCWs. Negative TSTs have higher reproducibility than QFT-GIT for serial testing of HCWs in low tuberculosis incidence settings.

Entities:  

Mesh:

Year:  2014        PMID: 24446969     DOI: 10.1513/AnnalsATS.201310-378OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  15 in total

1.  Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis Infection.

Authors:  Elisa Nemes; Virginie Rozot; Hennie Geldenhuys; Nicole Bilek; Simbarashe Mabwe; Deborah Abrahams; Lebohang Makhethe; Mzwandile Erasmus; Alana Keyser; Asma Toefy; Yolundi Cloete; Frances Ratangee; Thomas Blauenfeldt; Morten Ruhwald; Gerhard Walzl; Bronwyn Smith; Andre G Loxton; Willem A Hanekom; Jason R Andrews; Maria D Lempicki; Ruth Ellis; Ann M Ginsberg; Mark Hatherill; Thomas J Scriba
Journal:  Am J Respir Crit Care Med       Date:  2017-09-01       Impact factor: 21.405

2.  The dynamics of QuantiFERON-TB gold in-tube conversion and reversion in a cohort of South African adolescents.

Authors:  Jason R Andrews; Mark Hatherill; Hassan Mahomed; Willem A Hanekom; Monica Campo; Thomas R Hawn; Robin Wood; Thomas J Scriba
Journal:  Am J Respir Crit Care Med       Date:  2015-03-01       Impact factor: 21.405

3.  Risk of latent and active tuberculosis infection in travellers: a systematic review and meta-analysis.

Authors:  Tanya R Diefenbach-Elstob; Balqis Alabdulkarim; Paromita Deb-Rinker; Jeffrey M Pernica; Guido Schwarzer; Dick Menzies; Ian Shrier; Kevin Schwartzman; Christina Greenaway
Journal:  J Travel Med       Date:  2021-01-06       Impact factor: 8.490

Review 4.  Reproducibility of interferon gamma (IFN-γ) release Assays. A systematic review.

Authors:  Saloua Tagmouti; Madeline Slater; Andrea Benedetti; Sandra V Kik; Niaz Banaei; Adithya Cattamanchi; John Metcalfe; David Dowdy; Richard van Zyl Smit; Nandini Dendukuri; Madhukar Pai; Claudia Denkinger
Journal:  Ann Am Thorac Soc       Date:  2014-10

Review 5.  Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk Populations.

Authors:  Roland Diel; Niklas Lampenius; Albert Nienhaus
Journal:  Pharmacoeconomics       Date:  2015-08       Impact factor: 4.981

6.  US Postarrival Evaluation of Immigrant and Refugee Children with Latent Tuberculosis Infection Diagnosed Overseas, 2007-2019.

Authors:  Zanju Wang; Drew L Posey; Richard J Brostrom; Sapna Bamrah Morris; Nina Marano; Christina R Phares
Journal:  J Pediatr       Date:  2022-02-01       Impact factor: 6.314

7.  Testing of tuberculosis infection among Chinese adolescents born after terminating the Bacillus Calmette-Guérin booster vaccination: subgroup analysis of a population-based cross-sectional study.

Authors:  Hengjing Li; Henan Xin; Shukun Qian; Xiangwei Li; Haoran Zhang; Mufei Li; Boxuan Feng; Qi Jin; Lei Gao
Journal:  Front Med       Date:  2017-11-03       Impact factor: 4.592

8.  Paradox of serial interferon-gamma release assays: variability width more important than specificity size.

Authors:  J E Stout; R Belknap; Y-J Wu; C S Ho
Journal:  Int J Tuberc Lung Dis       Date:  2018-05-01       Impact factor: 3.427

9.  Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV.

Authors:  Adriana Weinberg; Lisa Aaron; Grace Montepiedra; Timothy R Sterling; Renee Browning; Blandina Mmbaga; Tichaona Vhembo; Shilpa Naik; Enid Kabugho; Gaerolwe Masheto; Savita Pahwa; Jyoti S Mathad; Sylvia M LaCourse; Katie McCarthy; Sarah Bradford; Gerhard Theron; Diane Costello; Bonnie Zimmer; Marie F Pierre; Kamunkhwala Gausi; Paolo Denti; David W Haas; Amita Gupta
Journal:  Clin Infect Dis       Date:  2021-11-02       Impact factor: 20.999

10.  Tuberculosis screening at the Sainte-Anne Hospital in Paris - results of first and second IGRA.

Authors:  Albert Nienhaus; Paul-Kenneth Gariepy; Catherine Trouve; Christiane Lhaumet; Jean Toureau; Claudia Peters
Journal:  J Occup Med Toxicol       Date:  2014-07-08       Impact factor: 2.646

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.